June 30, 2014
The Pharmaceutical Affairs and Food Sanitation Council’s (PAFSC) Second Committee on Drugs recommended approval of Bristol-Myers K.K.’s interferon (IFN)-free hepatitis C treatments daclatasvir and asunaprevir on June 26. If approved, the two products will be used in combination for the...read more